Answers are grounded in this paper and cite their sources.
Cancer remains a major global health challenge, necessitating the development of low-toxicity therapeutic agents. Huaier (Trametes robiniophila Murr.), a traditional Chinese medicinal fungus, has demonstrated significant multi-target anti-cancer potential. This review summarizes recent advances in understanding the molecular mechanisms and clinical applications of Huaier. Mechanistically, Huaier inhibits tumor cell proliferation, survival, and metastasis by modulating key signaling pathways, including Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3), phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), and Wnt/β-catenin, thereby inducing apoptosis, autophagy, and ferroptosis. Huaier has also been reported to suppress epithelial–mesenchymal transition (EMT) through pathways including G protein-coupled receptor 30 (GPR30)/PI3K/AKT and syntenin/STAT3. Furthermore, Huaier remodels the tumor microenvironment by regulating the gut microbiota, polarizing macrophages, enhancing CD8+ T cell infiltration, and inducing immunogenic cell death (ICD). Interestingly, Huaier also reverses chemoresistance and acts synergistically with chemotherapy, targeted therapy, and immunotherapy. Clinically, as an adjuvant treatment, Huaier has been shown to significantly improve overall survival and disease-free survival in patients with hepatocellular carcinoma, gastric cancer, and breast cancer, while reducing recurrence and improving quality of life. Nonetheless, despite the promising results, future research requires large-scale clinical trials and further exploration of the multi-component synergistic mechanisms of Huaier to fully elucidate the associated therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: